Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gane

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Viral Hepatitis|May 5, 2017
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patientsE Gane, R Nahass, V Luketic, et al.
Journal of Hepatology|February 7, 1998
The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipientsM McCarthy, J Ramage, A McNair, et al.
Transplantation Proceedings|December 1, 1994
Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinomaP M Rizzi, S D Ryder, J K Ramage, et al.
Gastroenterology|November 1, 1994
Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantationP M Rizzi, P A Kane, S D Ryder, et al.
Journal of Viral Hepatitis|December 28, 2016
HCV reinfection incidence among individuals treated for recent infectionM Martinello, J Grebely, K Petoumenos, et al.
The British Journal of Surgery|July 1, 1993
Orthotopic liver transplantation for hepatic complications of Wilson's diseaseM Rela, N D Heaton, V Vougas, et al.
The New England Journal of Medicine|December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis CS Zeuzem, S V Feinman, J Rasenack, et al.
Journal of Viral Hepatitis|June 14, 2016
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infectionE Gane, Z Ben Ari, L Mollison, et al.
Journal of Viral Hepatitis|August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)S D Shafran, D Shaw, M Charafeddine, et al.
Journal of Viral Hepatitis|April 17, 2018
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infectionM Martinello, S Bhagani, E Gane, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Viral Hepatitis|May 5, 2017
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patientsE Gane, R Nahass, V Luketic, et al.
Journal of Hepatology|February 7, 1998
The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipientsM McCarthy, J Ramage, A McNair, et al.
Transplantation Proceedings|December 1, 1994
Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinomaP M Rizzi, S D Ryder, J K Ramage, et al.
Gastroenterology|November 1, 1994
Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantationP M Rizzi, P A Kane, S D Ryder, et al.
Journal of Viral Hepatitis|December 28, 2016
HCV reinfection incidence among individuals treated for recent infectionM Martinello, J Grebely, K Petoumenos, et al.
The British Journal of Surgery|July 1, 1993
Orthotopic liver transplantation for hepatic complications of Wilson's diseaseM Rela, N D Heaton, V Vougas, et al.
The New England Journal of Medicine|December 7, 2000
Peginterferon alfa-2a in patients with chronic hepatitis CS Zeuzem, S V Feinman, J Rasenack, et al.
Journal of Viral Hepatitis|June 14, 2016
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infectionE Gane, Z Ben Ari, L Mollison, et al.
Journal of Viral Hepatitis|August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)S D Shafran, D Shaw, M Charafeddine, et al.
Journal of Viral Hepatitis|April 17, 2018
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infectionM Martinello, S Bhagani, E Gane, et al.
Pageof 6